Aptamer Group

Aptamer Group's mission is to overcome targeting challenges in life sciences by providing next-generation aptamer reagents and solutions. The company has achieved significant validation, claiming to work with 100% of the top 10 global pharmaceutical companies, and has demonstrated its technology in areas from Alzheimer's diagnostics to targeted siRNA delivery with AstraZeneca. Its strategy is to capture value in the $210 billion affinity ligand market through a fee-for-service and licensing model, progressing select programs into therapeutic development.

Proprietary Optimer® platform for the discovery and engineering of next-generation synthetic aptamers, designed for superior specificity, stability, and manufacturability compared to traditional antibodies.

Aptamer Group competes against the massive, entrenched antibody industry and other next-generation binder companies (e.g., Avacta's Affimers, Molecular Partners' DARPins). Its differentiation lies in its validated track record with top pharma, its nucleic acid-based Optimer platform offering distinct stability and manufacturing advantages, and its full-service custom development model.